03.01.2013
- Rare diseases are a growing focus for drug companies, with prices for some treatments for ultra-rare conditions running into hundreds of thousands of dollars a year. The following...
25.11.2010
- Genzyme Corp has met the first in a series of deadlines imposed by U.S. regulators for fixing problems at its Boston plant, a milestone that could bolster the biotech company's...
